BHI’s recent article on investing in the dental industry completely failed to mention Oragenics, even though its focus is exactly the kind of future technology that could give dental research a financial boost.
The little Florida biotech company is dedicated to researching and developing various antibody mediating therapies for human infections and other conditions, with primary focus on the oral cavity and periodontal tissues.
And why not develop an anti-caries vaccine? After all, dental caries (decay) is a bacterially transmitted contagious disease.
The biotechnology is in place and the mechanisms of the disease are being investigated and published.
The company’s most exciting product is MU1140, an oral antibiotic treatment that has the potential of immunizing humans against dental caries, commonly known as cavities.
The potential for such a treatment is tremendous. Imagine dental caries being eradicated much like polio, and other childhood conditions, through an immunization!
Oragenics also boasts an impressive lineup of research candidates, including mouth rinses shown to control many of the main disease causing bacterial species found in the human oral cavity.
If not Oragenics, then another company and set of investigators will develop, market and distribute a viable anti-caries vaccine within Flap’s lifetime.
Disclosure: Flap does not own any Biotechnology or Oragenics stock.
Technorati Tags: Caries, Vaccine, Oragenics, Mutacin1140